Home › Funds › Chesley Taft & Associates LLC › ABT

Chesley Taft & Associates LLC position in ABT

ABBOTT LABORATORIES · Health Care

Chesley Taft & Associates LLC reported holding 282,519 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$27.9M, representing 1.09% of its reported portfolio and ranking #23 among its reported holdings. Chesley Taft & Associates LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)282.52K sh
Reported value held$27.92M
Portfolio Weight1.09%
First reportedQ3 2023
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Chesley Taft & Associates LLC's ABT position evolved

Chesley Taft & Associates LLC first disclosed a stake in ABT in Q3 2023 at 236,373 shares (US$22.9M). The position peaked in Q2 2025 at 232,664 shares, worth US$31.6M. Across 13 filings, Chesley Taft & Associates LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 282,519 shares valued at US$27.9M — an increase of 2,835 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 236.37K $22.89M New
Q4 2023 237.50K $26.14M Hold
Q1 2024 237.29K $26.97M Hold
Q2 2024 238.05K $24.74M Hold
Q3 2024 236.17K $26.93M Reduce
Q4 2024 237.66K $26.88M Add
Q1 2025 234.06K $31.05M Reduce
Q2 2025 232.66K $31.64M Reduce
Q3 2025 223.16K $29.89M Reduce
Q4 2025 241.77K $30.29M Add
Q1 2026 242.63K $24.91M Hold
Q2 2026 279.68K $25.38M Add
Q3 2026 282.52K $27.92M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Chesley Taft & Associates LLC held ABT?

Chesley Taft & Associates LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Chesley Taft & Associates LLC's current position in ABT?

As of Q3 2026, Chesley Taft & Associates LLC holds 282.52K shares of ABT (ABBOTT LABORATORIES), valued at $27.92M, representing 1.09% of its reported portfolio and ranking #23.

Has Chesley Taft & Associates LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Chesley Taft & Associates LLC increased its position in ABT. The position peaked in Q2 2025 at 232.66K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.